Cost-effectiveness of a multicomponent-adherence intervention in fracture liaison services

Expert Rev Pharmacoecon Outcomes Res. 2024 Oct;24(8):987-996. doi: 10.1080/14737167.2024.2366439. Epub 2024 Jun 12.

Abstract

Background: This study aims to assess the lifetime cost-effectiveness of a multi-component adherence intervention (MCAI), including a patient decision aid and motivational interviewing, compared to usual care in patients with a recent fracture attending fracture liaison services (FLS) and eligible for anti-osteoporosis medication (AOM).

Research design and methods: Data on AOM initiation and one-year persistence were collected from a quasi-experimental study conducted between 2019 and 2023 in two Dutch FLS centers. An individual level, state-transition Markov model was used to simulate lifetime costs and quality-adjusted life years (QALYs) with a societal perspective of MCAI vs usual care. One-way and probabilistic sensitivity analyses were conducted including variation in additional FLS and MCAI costs (no MCAI cost in baseline).

Results: MCAI was associated with gain in QALYs (0.0012) and reduction in costs (-€16) and is therefore dominant. At the Dutch willingness-to-pay threshold of €50,000/QALY, MCAI remained cost-effective when increasing costs of the FLS visit or the yearly maintenance cost for MCAI up to +€60. Probabilistic sensitivity analysis demonstrated MCAI to be dominant in 54% of the simulations and cost-effective in 87% with a threshold of €50,000/QALY.

Conclusions: A MCAI implemented in FLS centers may lead to cost-effective allocation of resources in FLS care, depending on extra costs.

Keywords: Adherence; cost-effectiveness; fracture; fracture liaison services; osteoporosis; shared decision-making.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bone Density Conservation Agents* / administration & dosage
  • Bone Density Conservation Agents* / economics
  • Cost-Benefit Analysis*
  • Decision Support Techniques
  • Female
  • Humans
  • Male
  • Markov Chains*
  • Medication Adherence*
  • Middle Aged
  • Motivational Interviewing*
  • Netherlands
  • Osteoporosis / drug therapy
  • Osteoporosis / economics
  • Osteoporotic Fractures / economics
  • Osteoporotic Fractures / prevention & control
  • Quality-Adjusted Life Years*

Substances

  • Bone Density Conservation Agents

Grants and funding

This study was funded by the ZonMw research line Rational Pharmacotherapy, grant number 848016001. METC study number is METC2028-0507-A-10. The study was registered in the Netherlands Trial Registry, part of the Dutch Cochrane Centre (Trial NL7236 (NTR7435)). Version 1.0; 26-11-2020.